A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma.
Sonbol MB, Hilal T, Dueck AC, Rosenthal AC, Conley CR, Kosiorek HE, Ginos BF, Gano KM, Nichols CS, Leis JF, Johnston PB, Habermann TM, Northfelt DW, Bergsagel PL, Inwards DJ, Witzig TE, Ansell SM, Reeder CB.
Sonbol MB, et al. Among authors: inwards dj.
Leuk Lymphoma. 2018 Sep;59(9):2128-2134. doi: 10.1080/10428194.2017.1416368. Epub 2018 Jan 10.
Leuk Lymphoma. 2018.
PMID: 29320913
Clinical Trial.